Globally, one in four people will be affected by psychiatric or neurological disorders during their lifetime.1 With an estimated affected population of 450 million people, mental disorders are among the leading causes of ill-health and disability worldwide.1 At the recent Lundbeck Neuroscience Symposium held at Hilton Kota Kinabalu from 3–5 November 2017, three renowned key opinion leaders from the field of psychiatry shared their insights into the optimal management of bipolar disorder and schizophrenia.
At a recent Lundbeck Neuroscience Symposium at Hilton Kota Kinabalu, Professor Bernhard Baune discussed important clinical considerations in the management of behavioural and psychological symptoms of dementia (BPSD), focussing on the role of memantine hydrochloride (Ebixa®; Lundbeck).
In this issue of MIMS PsychiatrySupplement, we bring you clinical updates related to managing depression and optimizing functional recovery in patients with depression, as well as a symposium highlight of the Lundbeck Malaysia Neuroscience Symposium.
On 6 November 2016, in conjunction with the first year anniversary of vortioxetine (Brintellix®, Lundbeck) in Malaysia, two distinguished speakers, Professor Gin S Malhi and Dr Pranab Kalita shared updates on depression and the use of vortioxetine in order to help patients with major depressive disorders (MDD) to return to their premorbid functional states. The session was followed by three case presentations.
This article presents the excerpts from the Inaugural Meeting of the Dementia Advisory Board Malaysia held on 23 January 2016 in Kuala Lumpur, highlighting the clinical evidence of Ginkgo biloba extract EGb761® in dementia, treatment recommendations from international guidelines and consensus reached during the meeting on the role of EGb761® in managing dementia.
During the launch of Brintellix® (vortioxetine) in Malaysia, Professor Dr Nor Zuraida Zainal, Associate Professor Dr Gregory W Mattingly and Associate Professor Dr Ng Chong Guan provided an overview on depression, as well as expounded the role of vortioxetine in treating depression or major depressive episode.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Psychiatry - Malaysia digital copy today!
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.